Valeant Pharma revenue rises 36 pct

Mon Oct 19, 2015 6:08am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Oct 19 (Reuters) - Valeant Pharmaceuticals International Inc , which is under fire for massive price hikes of its two heart drugs, reported a 36 percent rise in quarterly revenue, as sales of dermatology products rose in the United States.

Net income attributable to the Canadian drugmaker fell to $49.5 million, or 14 cents per share, for the third quarter ended Sept. 30, from $275.4 million, or 81 cents per share, a year earlier.

Revenue rose to $2.79 billion from $2.06 billion.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D'Silva)